Vivus Inc: (NASD: VVUS)

$13.52

0.36 (2.74%)

Volume 2,897,349

May 22 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		13.17 - 13.58
	
		52wk Low - High
		9.86 - 31.21
	
		Previous Close
		13.16
	
		Avg. Volume
		2,521,147
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		1.32 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.22
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-1.91
	
		Quarterly Earnings ESP 
		-2.04%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		96 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/20/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -1.91
                        
                            Current Quarter Estimate
                            -0.49
                        
                            Most Accurate Estimate
                            -0.50
                        
                            Earnings ESP 
                            -2.04%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            -1.73
                        
                            Expected Earnings Growth
                            20.40%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS.   
Full VVUS Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
VVUS Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.49	-0.20	-1.91	-0.95
Number of Estimates	6	5	7	6
Low Estimate	-0.58	-0.59	-2.41	-1.81
High Estimate	-0.42	0.54	-1.06	NA
Year Ago EPS	-0.24	-0.40	-1.42	-1.91
EPS Growth	-104.17%	50.50%	-34.21%	50.15%

More VVUS Estimates

Average Earnings Estimates for VVUS

EPS Growth for VVUS

Industry Analysis

Name	Symbol	Previous Close
VIVUS INC	VVUS	13.16
AETERNA ZENTARS	AEZS	2.08
ANIKA THERAPEUT	ANIK	14.45
GENTIUM SPA-ADR	GENT	8.90
AASTROM BIOSCI	ASTM	0.57
ACADIA PHARMA	ACAD	13.79
ACHILLION PHARM	ACHN	7.75
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.45
ALEXION PHARMA	ALXN	102.67

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

ARNA Sheds Light on Belviq Launch

May 09, 2013

VIVUS Reports Wider Loss

May 09, 2013

CHMP Backs VIVUS' Spedra

Apr 30, 2013

The Zacks Analyst Blog Highlights: Merck, GlaxoSmithKline, VIVUS, Santarus and Celgene

Apr 30, 2013

Pfizer Likely to Report In Line Earnings

Apr 29, 2013

Merck Likely to Beat 1Q Earnings

Apr 29, 2013

Will Eli Lilly Beat Earnings in 1Q?

Apr 23, 2013

Will Amgen Beat Earnings?

Apr 22, 2013

More VVUS Zacks Commentary

Financials

EPS TTM	-1.73
Sales	2
Net Income	-175
Price/Earnings	NA
Price/Book	7.55
Price/Cash Flow	NA
Price/Sales	NA

More VVUS Financials

News

3 Pipeline Obesity Treatments You Should Watch - TheMotleyFool

May 22, 2013

VIVUS Announces Scientific Presentations - Globenewswire

May 22, 2013

VIVUS Q1 net loss increases - Datamonitor

May 22, 2013

Lazard Capital Made the Right Call, Vivus 3.9% Lower (VVUS) - Financial News Network Online - News Corner

May 21, 2013

The Surprising Link Between ADHD and Obesity - TheMotleyFool

May 21, 2013

VIVUS prices $200 million private placement of senior unsecured notes - Datamonitor Financial Deals Tracker

May 21, 2013

Earnings Look Back: Vivus Is Down 6.9% Since Reporting Quarterly Results 1 Week Ago (VVUS) - Comtex Smartrend(R)

May 20, 2013

Stock Investors Bid Up Shares of Vivus, Up 1.8% - Financial News Network Online - Market Movers

May 20, 2013

See All News Stories on VVUS

Broker Recommendations

Current ABR	2.40
ABR (Last Week)	2.40
# of recs in ABR	10
Average Target Price	18.85
Industry Rank by ABR	96 out of 265
Rank in Industry	37 out of 157

More VVUS Broker Recommendations

Day Low - High	13.17 - 13.58
52wk Low - High	9.86 - 31.21
Previous Close	13.16
Avg. Volume	2,521,147
Industry	MED-BIOMED/GENE
Market Cap	1.32 B
Div - Yield	0.00 - 0.00
Beta	1.22
PE (Forward)	0.00
Current Year Est.	-1.91
Quarterly Earnings ESP	-2.04%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-1.91
Current Quarter Estimate	-0.49
Most Accurate Estimate	-0.50
Earnings ESP	-2.04%
Next Earnings Report Date	08-06-2013
EPS Last Year	-1.73
Expected Earnings Growth	20.40%

Username: Password:

Remember me [?]

Vivus Inc: (NASD: VVUS)

$13.52

0.36 (2.74%)

Volume 2,897,349

May 22 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations